PEARCE IP
Our Capabilities
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.
With staff based in Australia and New Zealand, we coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.
Since its establishment in 2017 boutique Pearce IP has dominated in the area of pharmaceutical patents. Thanks to its deep bench of talented professionals, any life sciences brief is dispatched with alacrity and poise.
IP SPECIALIST LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS
Our Leaders
Naomi Pearce
CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)
Chris Coates (Maj Ret)
Executive, Finance
Helen Macpherson
Executive, Lawyer (Head of Litigation - Australia)
Kimberley Evans
Executive, Lawyer & Trade Mark Attorney (Head of Trade Marks - Australia)
Dr Mathew Lucas
Executive, Patent & Trade Mark Attorney
Paul Johns
Executive, Lawyer (Head of Litigation - New Zealand)
Julie Ballance
Executive, Patent Attorney and Trade Mark Practitioner (AU, NZ), Lawyer (NZ) & Notary (NZ)
Sally Paterson
Executive, Patent & Trade Mark Attorney (AU, NZ), Lawyer (NZ)
James Tocci
Executive, Corporate Services
Jacinta Flattery-O’Brien PhD
Special Counsel, Patent Attorney
Chantal Savage
Special Counsel, Lawyer
PEARCE IP BLOG
Read our latest updates & insights
Pearce IP Welcomes Two New Executives – Mathew Lucas and Mr James Tocci
Pearce IP is pleased to announce the appointment of two new executives strengthening the firm’s leadership capabilities and depth of expertise. Mathew Lucas PhD joins the Melbourne team as Executive Patent & Trade Mark Attorney. James Tocci joins as Executive, Corporate Services.
When Public Disclosure Destroys Novelty But Possibly Not Confidentiality…
This decision highlights the difference between disclosure under patent law and disclosure of confidential information and confirms that, just because an invention has been made “publicly available”, this does not mean that the invention has lost its confidential nature.
Pearce IP BioBlast® for the week ending 6 February 2026
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 February 2026 are set out below…
Product specific reports based on extracts from our BioBlast® database
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
dupilumab | Dupixent® | Sanofi-Aventis
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
guselkumab | Tremfya® | Janssen
infliximab | Remicade® | Johnson & Johnson
ixekizumab | Taltz® | Eli Lilly
lecanemab | Leqembi® | Eisai/Biogen
liraglutide | Victoza® /Saxenda® | Novo Nordisk
natalizumab | Tysabri® | Biogen/Elan
olaparib | Lynparza® | AstraZeneca/Merck
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | MSD
ranibizumab | Lucentis® | Genentech
regdanvimab | Regkirona® | Celltrion
risankizumab | Skyrizi® | AbbVie
rituximab | Rituxan®/MabThera® | Genentech/Biogen
secukinumab | Cosentyx® | Novartis
semaglutide | Wegovy®/Ozempic® | Novo Nordisk
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
ustekinumab | Stelara® | Johnson & Johnson/Janssen
OUR VISION
By 2027, be the premier life sciences IP practice in
Australia and New Zealand.
AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS
Awards
2024 IAM Strategy 300
Australasian Lawyer

MIP Stars
IAM Patent 1000 2024

Legal 500 2024




